Johnson & Johnson (JNJ)
| Market Cap | 392.64B |
| Revenue (ttm) | 88.82B |
| Net Income (ttm) | 14.07B |
| Shares Out | 2.41B |
| EPS (ttm) | 5.79 |
| PE Ratio | 28.14 |
| Forward PE | 15.42 |
| Dividend | $4.96 (3.04%) |
| Ex-Dividend Date | Feb 18, 2025 |
| Volume | 3,996,223 |
| Open | 162.84 |
| Previous Close | 163.63 |
| Day's Range | 162.54 - 164.39 |
| 52-Week Range | 140.68 - 169.99 |
| Beta | 0.46 |
| Analysts | Buy |
| Price Target | 170.75 (+4.8%) |
| Earnings Date | Apr 15, 2025 |
About JNJ
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizo... [Read more]
Financial Performance
In 2024, Johnson & Johnson's revenue was $88.82 billion, an increase of 4.30% compared to the previous year's $85.16 billion. Earnings were $14.07 billion, a decrease of -59.99%.
Financial StatementsAnalyst Forecast
According to 17 analysts, the average rating for JNJ stock is "Buy." The 12-month stock price forecast is $170.75, which is an increase of 4.80% from the latest price.
News
2 Dividend Picks Yielding Up To 5.67% For A Balanced Income & Growth Portfolio
I have added Canadian Natural Resources and NextEra Energy to The Dividend Income Accelerator Portfolio, each representing 2.19% of our overall portfolio. These strategic acquisitions help us to furth...
2025 Dividend Kings: Strong Run Continues
The Dividend Kings are outperforming the S&P 500 in 2025 by 4.57%. Top performers include National Fuel & Gas (+30.21%), Consolidated Edison (+22.66%), and AbbVie (+20.40%). Promising Dividend Kings i...
FDA Approves Johnson & Johnson's Tremfya For Crohn's Disease
On Thursday, the U.S. Food and Drug Administration (FDA) approved Johnson & Johnson's (NYSE JNJ) Tremfya (guselkumab), the first and only IL-23 inhibitor offering subcutaneous (SC) and intravenous (IV...
J&J plans to invest more than $55 billion in US over next four years
Johnson & Johnson said on Friday it plans to invest more than $55 billion over the next four years to build manufacturing facilities and research infrastructure in the United States.
Johnson & Johnson Increases U.S. Investment to More than $55 Billion Over the Next Four Years
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Today, Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare's leading, most comprehensive innovation powerhouse, announced manufacturing, research and develo...
U.S. FDA approves TREMFYA® (guselkumab), the first and only IL-23 inhibitor offering both subcutaneous and intravenous induction options, for adult patients with moderately to severely active Crohn's disease
TREMFYA® is the only IL-23i to demonstrate clinical remission and endoscopic response, both at one year, with a fully subcutaneous induction regimen Supported by data from the GALAXI study, TREMFYA® i...
Johnson & Johnson's Golden Cross: Technical Momentum Meets Groundbreaking Lung Cancer Breakthrough
Johnson & Johnson JNJ just hit a Golden Cross , a classic bullish technical pattern that signals potential long-term upside. The stock's 50-day simple moving average crossed above its 200-day simple m...
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE™ (lazertinib) significantly outperforms standard of care in first-line EGFR-mutated lung cancer with compelling new data at ELCC 2025
Median overall survival improvement projected to exceed one year with much-anticipated overall survival analysis showing statistically superior result versus osimertinib Preventative dermatologic regi...
Nipocalimab, the first and only investigational treatment to be granted U.S. FDA Breakthrough Therapy designation for the treatment of adults with moderate-to-severe Sjögren's disease, has now received Fast Track designation
Sjögren's disease (SjD) is a prevalent, debilitating autoantibody disease with no FDA-approved advanced treatments The Company is actively enrolling patients in the Phase 3 DAFFODIL study This ma...
Kenvue + Johnson & Johnson: I Choose To Own The Whole 'Humpty Dumpty'
Johnson & Johnson's spin-off of Kenvue has created two resilient defensive stocks in the healthcare sector, ideal for accumulation during market volatility. Despite being off their highs, both JNJ and...
An AI imaging firm says Johnson & Johnson stole its tech. Execs on both sides are expected to testify next week.
Johnson & Johnson executives are scheduled to take the stand in a trial starting Monday. ChemImage, a small biotech firm, sued the healthcare giant over a 2019 partnership that went south.
Lilly, J&J boosted spending on executive security after UnitedHealth shooting
U.S. drugmakers Johnson & Johnson and Eli Lilly increased spending on security for their top executives in 2024, with both citing increased threats after a UnitedHealth insurance executive was murdere...
Six Dean Omar Branham Shirley Attorneys Honored for Representation of Plaintiffs
DALLAS--(BUSINESS WIRE)--Leading plaintiff trial firm Dean Omar Branham Shirley, LLP is pleased to announce the selection of partners Jessica Dean, Amin Omar, Trey Branham, Lisa Shirley, Ben Braly and...
Cramer's Mad Dash: Johnson & Johnson
Jim Cramer breaks down why he's keeping an eye on shares of Johnson & Johnson.
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Icotrokinra meets primary endpoint of clinical response in ulcerative colitis study and shows potential to transform the treatment paradigm for patients
Topline results also show investigational targeted oral peptide icotrokinra achieved clinical remission rates up to 30.2% at Week 12 and a favorable safety profile in Phase 2b ANTHEM-UC study Clinical...
Icotrokinra results show potential to set a new standard of treatment in plaque psoriasis
Standout combination of complete skin clearance and favorable safety profile in a once daily pill could shift treatment paradigm Nearly half of patients with moderate-to-severe plaque psoriasis (PsO) ...
Pfizer Vs. Johnson & Johnson: Who's The Better Bargain For Investors
Johnson & Johnson and Pfizer occupy leading positions in the healthcare sector. Each of them has advantages, as well as dark spots in the portfolio of drugs relative to the comparator. In this article...
J&J to stop late-stage study of add-on depression drug
Johnson & Johnson said on Thursday it will discontinue a late-stage study of its add-on treatment for major depressive disorder due to insufficient efficacy in the target patient population.
10 Dividend Aristocrat Bargains To Help You SWAN During This Trade War Turmoil
The trade war is causing market volatility, with stocks falling and bonds performing well as investors seek hedges against economic slowdown fears. Dividend aristocrats, particularly low-volatility, d...
Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 15th to review first-quarter results. Joaqui...
5 Big Biopharmaceutical Stocks That Are Finding Favor
AbbVie, Gilead Sciences, Amgen, and Johnson & Johnson have held steady amid a fluctuating market.
Johnson & Johnson Announces Darren Snellgrove as Vice President, Investor Relations
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) (the “Company”) today announced the appointment of Darren Snellgrove to Vice President, Investor Relations. Jessica Moore, who has s...
Johnson & Johnson (JNJ) Presents at 45th Annual TD Cowen Healthcare Conference (Transcript)
Johnson & Johnson (NYSE:JNJ) 45th Annual TD Cowen Healthcare Conference March 4, 2025 11:10 AM ET Company Participants Tim Schmid - Executive Vice President, Worldwide Chairman, MedTech Conference Ca...